• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Cyclovirobuxine D

Cyclovirobuxine D

Product ID C9711
Cas No. 860-79-7
Purity ≥97%
Product Unit SizeCostQuantityStock
25 mg $128.00 In stock
100 mg $318.00 In stock
500 mg $1,086.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Cyclovirobuxine D is originally found in Buxus and displays cardioprotective and anticancer activities. Cyclovirobuxine inhibits the viability of breast cancer cells, inhibiting phosphorylation of Akt and mTOR and inducing autophagy. This compound also shows benefit in the treatment of heart failure but may prolong the QT interval through inhibition of human ether-a-go-go-related (hERG) K+ channel currents. Additionally, cyclovirobuxine D decreases infarct size and venous thrombus size in animal models of myocardial ischemia.

Product Info

Cas No.

860-79-7

Purity

≥97%

Formula

C26H46N2O

Formula Wt.

402.66

IUPAC Name

C26H46N2O

Synonym

Bebuxine, Cyclovirobuxine

Melting Point

219-224°C

Appearance

White crystal

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

C9711 MSDS PDF

Info Sheet

C9711 Info Sheet PDF

References

Lu J, Sun D, Gao S, et al. Cyclovirobuxine D induces autophagy-associated cell death via the Akt/mTOR pathway in MCF-7 human breast cancer cells. J Pharmacol Sci. 2014;125(1):74-82. PMID: 24758922.

Yu B, Fang TH, Lü GH, et al. Beneficial effect of Cyclovirobuxine D on heart failure rats following myocardial infarction. Fitoterapia. 2011 Sep;82(6):868-77. PMID: 21575690.

Zhao J, Wang Q, Xu J, et al. Cyclovirobuxine D inhibits the currents of HERG potassium channels stably expressed in HEK293 cells. Eur J Pharmacol. 2011 Jun 25;660(2-3):259-67. PMID: 21497594.

Hu D, Liu X, Wang Y, et al. Cyclovirobuxine D ameliorates acute myocardial ischemia by K(ATP) channel opening, nitric oxide release and anti-thrombosis. Eur J Pharmacol. 2007 Aug 13;569(1-2):103-9. PMID: 17555743.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • B8075

    4-tert-Butyl-5-Methoxy-1,2-quinone

    BHA derivative.

    ≥95%
  • R5611

    Rocuronium Bromide

    Non-depolarizing NMJ blocker; nAChR and M2/3 mA...

    ≥98%
  • P9668

    Pyrantel Pamoate

    Mixture of pyrantel, a thiophene, and pamoic ac...

    ≥98%
  • C9809

    Cyclopiazonic Acid

    SERCA inhibitor.

    ≥98%, TLC
  • M9608

    Myclobutanil

    14-α demethylase inhibitor.

    ≥97%
  • M9356

    Myomodulin

    Proton pump inhibitor

    ≥95%
  • F0275

    Fasudil Hydrochloride

    ROCK inhibitor.

    ≥98%
  • R5212

    RN-486

    Btk inhibitor.

    ≥98%
  • T1853

    Tenovin-6

    SIRT1/2 inhibitor, indirect p53 activator.

    ≥98%
  • B5728

    Bohemine

    Purine derivative; CDK inhibitor.

    ≥98%
  • C0273

    Casin

    Cdc42 GTPase inhibitor.

    ≥97%
  • B030967

    BAY-1895344

    ATR inhibitor.

    ≥99%
  • M1845

    Melitracen Hydrochloride

    Tricyclic antidepressant; potential D1/2 antago...

    ≥99%
  • F5773

    Fosinopril Sodium

    ACE inhibitor.

    ≥98%
  • G880000

    GW 405833

    Cannabinoid receptor 2 selective agonist.

    ≥98%
  • E2542

    Met-Enkephalin Amide

    Endogenous opioid peptide; δOR and μOR agonis...

    ≥95%
  • S6800

    SR1001

    RORα/γ inverse agonist.

    ≥99%
  • I4659

    Iloperidone

    Benzisoxazole phenylethanone; D2 and 5-HT2A ant...

    ≥99%
  • C7997

    C-Type Natriuretic Peptide (1-22), human

    Endogenous cardiomodulatory peptide; NPR-B agon...

    ≥95%
  • D6958

    Droloxifene Citrate

    Tamoxifen analog; SERM.

    ≥98%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only